Open AccessEfficacy of somatostatine analogues in survival and quality of life of a frail patient with poorly differentiated biliary neuroendocrine tumour
Author(s) -
Marco Alì,
Antonino D’Agostino,
A. Todaro,
A. Girlando,
M Ferrara,
R. Aiello
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i1s.1065
Subject(s) - medicine , quality of life (healthcare) , octreotide , neuroendocrine tumors , radiation therapy , multidisciplinary team , neuroendocrine differentiation , stage (stratigraphy) , oncology , neuroendocrine carcinoma , gastroenterology , cancer , somatostatin , carcinoma , nursing , paleontology , biology , prostate cancer
We describe the case of a 71-year-old woman with poorly differentiated neuroendocrine tumor of third distal biliary duct and osteolytic metastasis. The patient was evaluated as a third stage of Balducci’s criteria for the recognition of frailty. The patient received radiotherapy and octreotide LAR. This treatment allowed a good tumour progression rate (18 months), a good quality of life and a good survival (35 months). The case report describes the role of octreotide in the therapy of neuroendocrine tumours, and underlines the importance of a multidisciplinary management of cancer in frail patients.